Tudy exclusion criteria included chronic neurological disorder, head injury, uncontrolled seizure disorder, experimental drugs or vaccination within the past 15 days, radiation or chemotherapy within prior month, mental condition involving inability to understand, chronic alcohol or drug abuse, pregnancy, opportunistic infection, cancer, medical condition (heart, liver or kidney) or MR contraindic
Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres
Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres
Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres
Tudy exclusion criteria included chronic neurological disorder, head injury, uncontrolled seizure disorder, experimental drugs or vaccination within the past 15 days, radiation or chemotherapy within prior month, mental condition involving inability to understand, chronic alcohol or drug abuse, pregnancy, opportunistic infection, cancer, medical condition (heart, liver or kidney) or MR contraindic
Nd were processed for assays or cryopreservation of blood components within 28 hours of phlebotomy. Lymphocyte proliferative responses to whole protein antigens were measured using a membrane dye dilution methodology adapted from da Silva et al [15]. PBMC were treated with 8M PKH26, a fluorescent membrane dye, using the manufacturer's protocol (Sigma Chemical Co.), then cultured in duplicate at 2
Lar haplotype assays (BioTest ABC SSPtray; BioTest Diagnostics Corp, Denville, NJ). Vaccinia-specific CD8 T-cell IFN and MIP-1 production was by flow cytometry measured using stimulation with live vaccinia virus (NYCBH strain) at an MOI of 5 as described by Precopio et al [18]. ELISPOT assays were performed utilizing MabtechTM ELISpot plus Human Interferon-gamma kits (MABTECH AB, Sweden). Cryopres
Nclusion criteria included: plasma HIV RNA levels (plasma viral load) 350 cells/mm3; and clinically healthy with all laboratory values grade